Literature DB >> 9258223

Uveal melanoma. Growth rate and prognosis.

D H Char1, S Kroll, T L Phillips.   

Abstract

OBJECTIVE: To study in vivo tumor growth rates, doubling times, and the association of these parameters with local tumor control and melanoma-related mortality.
METHODS: We retrospectively reviewed uveal melanomas with documented growth on serial evaluations before treatment. The tumor dimensions were based on clinical measurements for tumor diameters and quantitative echography to determine tumor thickness. One hundred forty-five patients met study criteria. All tumors were initially measured by the same observer with the same techniques, and, in 133 cases, serial observations and treatment were performed at our institution.
RESULTS: Tumor-doubling time estimates were log normally distributed, with a median of 1.4 years. Those 13 patients in whom metastases developed tended to have more rapid tumor growth rates. Iodine 125 brachytherapy failed in 8 patients with more rapidly growing tumors.
CONCLUSIONS: Faster growing tumors appear to be more likely to develop early metastases and have failure of local radiation control.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258223     DOI: 10.1001/archopht.1997.01100160184007

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  15 in total

Review 1.  The Zimmerman-McLean-Foster hypothesis: 25 years later.

Authors:  A D Singh; I G Rennie; T Kivela; S Seregard; H Grossniklaus
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

Authors:  E Richtig; G Langmann; G Schlemmer; K Müllner; G Papaefthymiou; P Bergthaler; J Smolle
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

3.  Mode of presentation and time to treatment of uveal melanoma in Finland.

Authors:  S Eskelin; T Kivelä
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

4.  Rapid growth of primary uveal melanoma following intravitreal bevacizumab injection: a case report and review of the literature.

Authors:  Jingyi Ma; Kelsey A Roelofs; Laurie Russell; Ezekiel Weis; Sylvia H Chen
Journal:  Digit J Ophthalmol       Date:  2020-07-03

5.  Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.

Authors:  Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

6.  Uveal melanoma with extrascleral extension and systemic metastasis complicating into retinal detachment and cataract formation.

Authors:  Shivcharan L Chandravanshi; Sujata Lakhtakia; Mahesh K Rathore; Prem C Dwivedi; Jainendra S Rahud
Journal:  Indian J Ophthalmol       Date:  2010 May-Jun       Impact factor: 1.848

7.  Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma.

Authors:  I Kaiserman; I Anteby; I Chowers; E Z Blumenthal; I Kliers; J Pe'er
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

Review 8.  Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.

Authors:  Jose J Echegaray; Nikolaos E Bechrakis; Nakul Singh; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-08

9.  Late Apical Recurrence of Choroidal Melanoma 10 Years after Successful Treatment with Brachytherapy.

Authors:  Grace C Shih; Bao Han A Le; Zelia M Correa; Maria E Sibug-Saber; Jonathan W Kim; Jesse L Berry
Journal:  Ocul Oncol Pathol       Date:  2017-12-22

Review 10.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.